363 articles with Bayer AG
The filing to the U.S. District Court District of New Jersey, dated December 31st, 2020, states that the materials include compound data, strategic plans related to translational and biomarker data, therapeutic program reviews, abstract publications, plans for Congressional presentations, drug mo...
Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need
Harnessing the human skin microbiome to develop cutting-edge solutions moving the paradigm from treatment to cure in dermatology
Vincera Pharma, Inc Announces Exclusive License Agreement for Oncology Portfolio Including a Clinical-stage PTEFb/CDK9 Inhibitor and a Preclinical Bioconjugation Platform
P ortfolio includes VIP152, a highly selective PTEFb /CDK9 inhibitor with encouraging Phase 1 monotherapy activity , including complete responses in DH-DLBCL Vincera intends to pursue multiple accelerated approval opportunities in M YC - and MCL1- driven cancers Preclinical bioconjugation platform designed to overcome limitations of small - molecule and antibody - drug conjugates use to treat cancer SANTA CLARA, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE)
Bayer and Northpond Ventures Lead USD 55 million Series A Financing Round for Triumvira Immunologics
Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments
Bayer and Temasek Unveil Innovative New Company Focused on Developing Breakthroughs in Vertical Farming
Called Unfold, the new company will be headquartered in the Davis, Calif., area with key operations in both the U.S. and Singapore
Global life sciences leader selects Vault Study Startup and Vault eTMF to improve trial efficiency
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
Phase 3 VICTORIA Trial is the First Contemporary Outcomes Study Focused Exclusively on a Chronic Heart Failure Patient Population Following a Worsening Event
Elanco Signs Agreement with Vetoquinol to Divest Rights for Drontal® and Profender® Within the European Economic Area and the United Kingdom
Elanco Animal Health Incorporated announced it has signed an agreement to divest the European Economic Area and UK rights to the Drontal® and Profender® product families from Bayer AG’s animal health business, to Vetoquinol SA, a French pharmaceutical company, for $140 million in an all-cash deal subject to customary post-closing adjustments.
Evotec SE announced that its partner Bayer AG has decided to advance a further programme from the endometriosis multi-target alliance into clinical Phase I development.
Elanco Animal Health Announces Common Stock and Tangible Equity Unit Offerings Associated with Financing Acquisition of Bayer’s Animal Health Business
Elanco Animal Health Incorporated announced it intends to make concurrent public offerings of 19,159,866 shares of its common stock and 11,000,000 tangible equity units, with an aggregate stated amount of $550 million for the units.
Bayer AG and its Monsanto subsidiary are hoping to minimize losses at the expense of nearly 43,000 cancer victims who have filed suit after falling ill following exposure to the popular weed killer Roundup.
Evotec and Bayer Announce New Alliance Focusing on Drug Discovery for Polycystic Ovary Syndrome With Novel Targets From Celmatix
New five-year, multi-target alliance aims to translate first-in-class science and drug discovery into new drugs for polycystic ovary syndrome
Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery
Exscientia, the leading Artificial Intelligence -driven drug discovery company, announced today that it has entered a collaboration with Bayer AG that aims to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Simulations Plus Partners with Bayer AG to Develop New Cheminformatics Capabilities in ADMET Predictor
New Structure and Tautomer Handling Routines Aim to Improve Data Integrity in Drug Discovery
ProBioGen AG announced the closing of a license agreement with Bayer AG for the GlymaxX® Technology.
Another successful outcome from a Versant-created company in a breakthrough field
Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell platform.
Parasitic Diseases Therapeutics Market Worth USD 1.79 Billion, at 5% CAGR During 2019-2023 | Technavio
According to Technavio Research Report "Parasitic Diseases Therapeutics Market by type and geographic regions is witnessed to grow USD 1.79 billion, at a CAGR of 5% from 2019 to 2023”.
Bayer and Foundation Medicine announce global collaboration to develop next-generation sequencing (NGS)-based companion diagnostics in oncology
Bayer AG and Foundation Medicine, Inc. announced a global collaboration for the development and commercialization of NGS-based companion diagnostics.